Serum miR-18a: A Potential Marker for Hepatitis B Virus-Related Hepatocellular Carcinoma Screening
Digestive Diseases and Sciences, 08/16/2012Li L et al.
The results suggest that serum microRNAs (miRNAs)–18a might serve as a novel and potential noninvasive biomarker for hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC) screening.
This study was divided into two phases: firstly, marker (miR-95, miR-18a, miR-10b, miR125a, and miR-378) detection by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) in sera from HBV patients with HCC (n=15) and health subject (n=15); and, secondly, marker validation by real-time qRT-PCR on HBV patients with HCC (n=86) or hepatitis or cirrhosis (n=30), and healthy subject (n=45).
Serum miR-18a was significantly higher in HBV patients with HCC than healthy controls (p < 0.01); serum miR-378 was significantly lower in HBV patients with HCC compared to healthy control (p<0.05).
Receiver operating characteristic (ROC) curve analyses suggested that serum miR-18a had significant diagnostic value for HBV-related HCC.
MiR-18a yielded an area under the curve (AUC) of ROC of 0.881 with 86.1 % sensitivity and 75.0 % specificity in discriminating HBV-related HCC from healthy controls, and an AUC of ROC of 0.775 with 77.2 % sensitivity and 70.0 % specificity in discriminating HBV-related HCC from chronic hepatitis or cirrhosis.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.